Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glatiramer acetate versus no treatment for retinal nerve fiber layer changes in CIS or early RRMS
2009-013129-41Phase 4Active
- Sponsor
- Amphia Ziekenhuis
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of glatiramer acetate in clinically isolated syndrome (CIS) and multiple sclerosis (MS) (2 arms), sponsored by Amphia Ziekenhuis. Primary endpoints: Feasibility of OCT measurement, Mean change in retinal nerve fiber layer thickness and 1 more. Started Jun 2009; status: active.
02
Drugs
glatiramer acetate
03
Conditions
clinically isolated syndrome (CIS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-013129-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013129-41.